Replies to post #9061 on Innovus Pharmaceuticals Inc. (fka INNV)

[Biotech Pharmer]

Nobody has asked about or mentioned how going with the Westward ANDA will affect marketing and labeling costs. I'm guessing a new manufacturerit will involve a new labeling application and more unnecessary costs. Why pay once for something when you can pay twice. I agree with your assessment of Damaj. An unsavory combination of BS and ineptitude. The Pink Sheets, folks. There's a reason he's not at Merck or Pfizer

[sweetstreet]

Based on what? Aside from the unanticipated delay in the original ANDA, which was known before yesterday's call by the way, what are they doing that wasn't advertised? Conserving cash, significant reduction in operating expenses, on pace for $15M revenue (30% increase from last quarter, and Damaj indicates they'll be profitable within the $10-15M mark), and the most telling of all...that they gave up nothing additional for the West-Ward deal. On the last point alone, shorty should run for cover.